KMT2A and acute lymphoblastic leukemia: A particularly difficult clinical issue is that MLL-r B-ALL retains lineage plasticity and infidelity—following treatment with CD19 CAR T-cell therapy or monoclonal antibodies MLL-AF4 ALL can undergo a lineage switch [7].